

Special Issue

STAT3 a Moonlighting Protein: Focus on Its Post-translational Modifications and Protein Interactors

Message from the Guest Editors

The signal transducer and activator of transcription 3 (STAT3) is a protein with polyhedral activities: it mediates, directly or indirectly, multiple cellular signaling pathways (cytokines of growth factors, hormones and oxidative stress). In addition, it is a key protein in the modulation of metabolism and mitochondrial activity and it is involved in the regulation of microtubule dynamics in the cellular cytoskeleton.

STAT3 activation is crucial in various diseases such as chronic inflammation, cardiovascular and metabolic disorders and cancer. STAT3 can be considered a moonlighting protein and its multifaceted activities are mainly exerted via post-translational modifications such as phosphorylation, acetylation, glutathionylation and methylation and interaction with a variety of protein components. This Special Issue aims to investigate the key role of STAT3, its PTMs and its protein ligands in the modulation of cellular functions. We hope that researchers in the field will contribute with research articles, review articles, innovative hypotheses or commentaries on STAT3-related activities and regulations.

Guest Editors

Dr. Margherita Eufemi

Department of Biochemical Sciences, Università degli Studi di Roma La Sapienza, Rome, Italy

Dr. Donatella Romaniello

1. Department of Medical and Surgical Sciences (DIMEC), University of Bologna, Via Massarenti 9, 40138 Bologna, Italy

2. IRCCS Azienda Ospedaliero-Universitaria di Bologna, Via Massarenti 9, 40138 Bologna, Italy

Deadline for manuscript submissions

closed (31 December 2022)



Biomedicines

an Open Access Journal
by MDPI

Impact Factor 3.9
CiteScore 6.8
Indexed in PubMed



mdpi.com/si/75078

Biomedicines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
biomedicines@mdpi.com

[mdpi.com/journal/
biomedicines](https://mdpi.com/journal/biomedicines)





Biomedicines

an Open Access Journal
by MDPI

Impact Factor 3.9
CiteScore 6.8
Indexed in PubMed



[mdpi.com/journal/
biomedicines](https://mdpi.com/journal/biomedicines)



About the Journal

Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

Editor-in-Chief

Prof. Dr. Felipe Fregni

1. Neuromodulation Center and Center for Clinical Research Learning, Spaulding Rehabilitation Hospital and Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
2. Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, CAPUS / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Medicine (miscellaneous))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 17 days after submission; acceptance to publication is undertaken in 2.9 days (median values for papers published in this journal in the first half of 2025).